Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
GSK sees phase 3 win for Hansoh-partnered ADC in China as validating its ‘priority asset’
(19h)
Bausch + Lomb gives up on glaucoma eye drop hopeful after phase 2 fail
(23h)
ARPA-H awards up to $160M to scientists developing custom genetic medicines
(1d)
BioPharma Dive
GSK, Hansoh ADC extends survival in lung cancer study
(16h)
ARPA-H puts $160M into bespoke drug therapies; Biohaven switches up scientific leadership
(20h)
Roche scraps two Ionis-partnered Huntington’s drugs
(1d)
Endpoints News
Apnimed files for IPO as FDA reviews its sleep apnea drug
(10h)
FDA returns to releasing pharma rejection letters with 14 new CRLs
(13h)
FDA rejects Hengrui-Elevar liver cancer drug combo for third time
(14h)
BioSpace
From sequence to scale: Gene editing’s new era in biologics manufacturing
(16h)
AAIC 2026: Tau-targeted Alzheimer’s treatments heat up while amyloid therapies persist
(17h)
GSK and Hansoh’s ADC clinches late-stage win, teeing up regulatory submission in China
(18h)
STAT News
Nominee for key federal health role has a history of questioning vaccines
(12h)
Roche ends Huntington’s gene-silencing programs
(18h)
We’re reading about bigger drug discounts in Germany, drugmakers embracing secrecy, and more
(19h)
BioPharma Trend
Seven HealthTech Trends In Europe To Watch
(2w)
Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.
(3w)
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(1mo)
Drug Channels
When Access Tightens, Prior Authorization Execution Becomes the Differentiator
(21h)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
The Hidden Cost of 340B for Employers and Health Plans
(2d)
European Biotechnology Magazine
Roche drops two Huntington’s programmes from Ionis
(23h)
AstraZeneca and Ionis miss in key ATTR-CM trial
(1d)
GSK ends Alector neuroscience deal after trial failures
(1d)
Drug Hunter
How to “pHLIP” the Script on Drug Delivery
(17h)
ACT-1004-1239
(1d)
TERN-701
(2d)
Labiotech.EU
Top biotech deals in June 2026
(18h)
Turning cancer cell dependencies into targeted therapies
(1d)
11 biotech companies leading the way in Denmark
(2d)
Bio IT World
Signal Management Isn’t Broken; It Simply Belongs to a Previous Era
(1d)
Network Effects: John Quackenbush on How Networks Illuminate Biology Beyond Gene Expression
(2d)
Insilico Medicine Launches Phase III Trial for AI-Developed Drug
(3d)
GEN News
Macrophage Membrane-Derived Nanoparticles Shows Potential Against Candida Infections
(15h)
Epigenomic Analysis Uncovers New AML Subgroups and Drug Sensitivities
(1d)
Stem Cell Therapy Shows Promise in First Human Parkinson’s Disease Trial
(1d)
Cure Today
A Simple Calf, Hamstring & Low Back Relief Routine for Patients With Cancer
(2d)
What Patients Should Know About Preparing for Cell Therapy
(2d)
Targeted therapy in Lung Cancer Care: What the Research Shows
(2d)
Contract Pharma
The Friday Brief for July 10, 2026: Companies and Facilities Changing Hands
(18h)
Biohaven Announces Scientific Leadership Changes
(19h)
Takara Bio USA President and CEO Carol Lou to Retire, Succeeded by Andrew Farmer
(1d)
Pharma Times
Pluripotent stem cell trial for Huntington’s disease
(2d)
Jascayd gains UK licence for treatment of pulmonary fibrosis
(2d)
Grünenthal receives FDA designations for tegacorat in Duchenne muscular dystrophy
(3d)
Medcity News
What Is AI Getting Right — and Wrong — in Healthcare’s Revenue Cycle?
(3w)
KFF: Insurer Participation in ACA Marketplaces Is Down
(3w)
FDA Reversal on uniQure Gene Therapy Is Another Sign of Renewed Regulatory Flexibility
(3w)
Chemical & Engineering News
Memory Lane: Cultivating a right to science education
(12h)
Policy Watch: FDA rejects petition to set PFAS limits in certain foods
(13h)
Chemists get twice the reactivity from a single substitution handle
(16h)
The Pharma Letter
Padcev-Keytruda wins broader FDA approval in bladder cancer
(13h)
FDA thumbs up for Sanofi’s subcutaneous Sarclisa Escena
(16h)
Hansoh reports positive Phase III China data for GSK-partnered Ris-Rez in small cell lung cancer
(17h)
Targeted Oncology
FDA Accepts NDA for Varegacestat in Desmoid Tumors
(2d)
Oral CELMoD Golcadomide Advances in Relapsed FL
(2d)
Implementing a Bispecific Antibody Program in Community Oncology—Insights From the American Oncology Network
(2d)
MedWatch
Mikael Dolsten takes chair at AI company BenchSci after withdrawing from Novo Nordisk board race
(19h)
After years of delays: MagCath's female catheter greenlighted for sale in Europe
(19h)
Biotech CEO on new Novo Nordisk partnership: “This could be big”
(20h)
In The Pipeline
Chemical Onshoring of All Kinds
(1d)
Turning Down the Refinery Heat
(2d)
A Telomerase Inhibitor Revealed
(3d)
Pharmaphorum
Non-profit DNDi preps phase 3 trials for dengue antibody
(21h)
Bausch + Lomb drug fails in glaucoma, but a new use beckons
(22h)
Roche abandons two Huntington's drug candidates
(23h)
Drug Discovery Weekly
Wegovy pill could help patients lose 17% body weight
(3w)
How AskBio is pioneering ‘transformative genetic therapies’ in Parkinson’s disease
(3w)
Webinar: Learn how to accelerate the early stages of drug discovery
(3w)
HIT Consultant
Health Payers Have Invested in Modern Data Infrastructure. Access Control Hasn’t Kept Up.
(1d)
The Technology Gap Holding Provider-Sponsored Health Plans Back
(1d)
Grounding Clinical AI in Evidence: The Critical Role of Human Oversight and Continuous Validation
(1d)
Insights: Pink Sheet
US FDA Proposes One Registration For Distributed Drug Manufacturing Networks
(10h)
US FDA Hiring Binge: CDER, CBER Report Q3 Bump, First Since Trump Administration Cuts
(12h)
Unpause? US FDA Posts 14 New CRLs After Temporary Halt
(14h)
BioXconomy
Germany doubles pharma rebates to curb costs
(15h)
Legislative changes alter GTN landscape
(20h)
Sandoz launches direct-to-patient drug platform
(20h)
BioCentury
With first clinical data due next year, Scribe to test IPO market: Finance Report
(7h)
FDA resumes CRL releases, citing ‘commitment to transparency’
(7h)
Perspective — siRNAs are better than ASOs
(9h)
SCRIP
Gilead’s Biggest Buys Balance Drug Candidate Needs With Platform Desires
(11h)
Roche Pulls Plug On Two Antisense Oligonucleotide Programs In Huntington’s
(11h)
Pharma At The Midyear: Taking Stock Of Financial Forecasts
(11h)